310 related articles for article (PubMed ID: 22551459)
1. HER2 amplification status in gastric and gastro-oesophageal junction cancer in routine clinical practice: which sample should be used?
Perrone G; Amato M; Callea M; Rabitti C; Righi D; Crucitti P; Coppola R; Onetti Muda A
Histopathology; 2012 Jul; 61(1):134-5. PubMed ID: 22551459
[No Abstract] [Full Text] [Related]
2. Isolated CNS relapse in human epidermal growth factor receptor 2-positive esophagogastric cancer: effective treatment with trastuzumab after failure of surgery and radiotherapy.
Geldart T; Astras G
J Clin Oncol; 2011 Aug; 29(23):e664-5. PubMed ID: 21646609
[No Abstract] [Full Text] [Related]
3. Early HER2 dysregulation in gastric and oesophageal carcinogenesis.
Fassan M; Mastracci L; Grillo F; Zagonel V; Bruno S; Battaglia G; Pitto F; Nitti D; Celiento T; Zaninotto G; Fiocca R; Rugge M
Histopathology; 2012 Nov; 61(5):769-76. PubMed ID: 22882541
[TBL] [Abstract][Full Text] [Related]
4. Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment.
Maresch J; Schoppmann SF; Thallinger CM; Zielinski CC; Hejna M
Crit Rev Oncol Hematol; 2012 Jun; 82(3):310-22. PubMed ID: 21783379
[TBL] [Abstract][Full Text] [Related]
5. Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas.
Fassan M; Ludwig K; Pizzi M; Castoro C; Guzzardo V; Balistreri M; Zaninotto G; Ruol A; Giacomelli L; Ancona E; Rugge M
Hum Pathol; 2012 Aug; 43(8):1206-12. PubMed ID: 22217477
[TBL] [Abstract][Full Text] [Related]
6. HER2 status in gastric/gastro-oesophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2: CEP17 ratio?
Kumarasinghe MP; de Boer WB; Khor TS; Ooi EM; Jene N; Jayasinghe S; Fox SB
Pathology; 2014 Apr; 46(3):184-7. PubMed ID: 24614718
[TBL] [Abstract][Full Text] [Related]
7. Targeted HER2 treatment in advanced gastric cancer.
Jørgensen JT
Oncology; 2010; 78(1):26-33. PubMed ID: 20185938
[TBL] [Abstract][Full Text] [Related]
8. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
Hechtman JF; Polydorides AD
Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
[TBL] [Abstract][Full Text] [Related]
9. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?
Lorenzen S; Lordick F
Curr Opin Oncol; 2011 Jul; 23(4):396-402. PubMed ID: 21505336
[TBL] [Abstract][Full Text] [Related]
10. HER-2 discordance between primary gastric carcinoma and paired lymph node metastasis.
Negri FV; Bozzetti C; Ardizzoni A; Lagrasta C; Crafa P; Silini EM
Hum Pathol; 2011 Jun; 42(6):909-10; author reply 910-1. PubMed ID: 21571126
[No Abstract] [Full Text] [Related]
11. Analysis of HER2 expression and gene amplification in adenocarcinoma of the stomach and the gastro-oesophageal junction: rationale for the Belgian way of working.
Jouret-Mourin A; Hoorens A; De Hertogh G; Vanderveken J; Demetter P; Van Cutsem E
Acta Gastroenterol Belg; 2012 Mar; 75(1):9-13. PubMed ID: 22567741
[TBL] [Abstract][Full Text] [Related]
12. Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma.
Kaur A; Dasanu CA
Expert Opin Pharmacother; 2011 Nov; 12(16):2493-503. PubMed ID: 21967344
[TBL] [Abstract][Full Text] [Related]
13. HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer.
Inui T; Asakawa A; Morita Y; Mizuno S; Natori T; Kawaguchi A; Murakami M; Hishikawa Y; Inui A
J Intern Med; 2006 Nov; 260(5):484-7. PubMed ID: 17040255
[No Abstract] [Full Text] [Related]
14. A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.
Gomez-Martín C; Lopez-Rios F; Aparicio J; Barriuso J; García-Carbonero R; Pazo R; Rivera F; Salgado M; Salud A; Vázquez-Sequeiros E; Lordick F
Cancer Lett; 2014 Aug; 351(1):30-40. PubMed ID: 24943493
[TBL] [Abstract][Full Text] [Related]
15. HER2 testing in gastric cancer.
Albarello L; Pecciarini L; Doglioni C
Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
[TBL] [Abstract][Full Text] [Related]
16. The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis.
Fassan M; Pizzi M; Realdon S; Balistreri M; Guzzardo V; Zagonel V; Castoro C; Mastracci L; Farinati F; Nitti D; Zaninotto G; Rugge M
Hum Pathol; 2013 Sep; 44(9):1804-10. PubMed ID: 23618359
[TBL] [Abstract][Full Text] [Related]
17. HER2 Genetic Heterogeneity in Gastric Cancer: Evaluation According to the College of American Pathologists Breast Cancer Criteria.
Treacy AD; Karamchandani JR; Streutker CJ; Grin A
Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):628-32. PubMed ID: 25611242
[TBL] [Abstract][Full Text] [Related]
18. Update on Gastroesophageal Adenocarcinoma Targeted Therapies.
Maron SB; Catenacci DVT
Hematol Oncol Clin North Am; 2017 Jun; 31(3):511-527. PubMed ID: 28501091
[TBL] [Abstract][Full Text] [Related]
19. HER2 testing in gastric cancer: a practical approach.
Rüschoff J; Hanna W; Bilous M; Hofmann M; Osamura RY; Penault-Llorca F; van de Vijver M; Viale G
Mod Pathol; 2012 May; 25(5):637-50. PubMed ID: 22222640
[TBL] [Abstract][Full Text] [Related]
20. EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus.
Birkman EM; Ålgars A; Lintunen M; Ristamäki R; Sundström J; Carpén O
BMC Cancer; 2016 Jul; 16():406. PubMed ID: 27387915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]